No Data
Curve Therapeutics Further Strengthens Leadership Team With the Appointment of Andre Hoekema as New Chair of Board
Express News | Excellos, Cell Therapy Contract And Development Manufacturing Organization Member Of Blood Centers Of America Has Been Selected To Manufacture Galapagos' Car-t Cell Therapy Candidate, GLPG5101, For Its Recently FDA-Cleared ATALANTA-1 Study For...
Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area
Galapagos Announces Major Stake by EcoR1 Capital
Galapagos Receives Transparency Notification From EcoR1 Capital, Now Holding 10.19% Of Galapagos' Voting Rights Through Acquisition Of 6.71M Shares; EcoR1 Capital Crosses 10% Threshold As Of September 10, 2024
Galapagos Analyst Ratings
whqqq : Thank you for your comprehensive sharing